medigraphic.com
Academia Mexicana de Neurología, A.C.

2011, Number 2

<< Back Next >>

Rev Mex Neuroci 2011; 12 (2)

Rational pharmacotherapy in Epilepsy

Rodríguez LI

Language: Spanish
References: 27
Page: 87-94
PDF size: 159.37 Kb.


ABSTRACT

Epilepsy is one of the most common neurological disorders at any age. The risk of developing epilepsy during lifespan is around 3.2%. Treatment of epilepsy is base on the etiology, seizures type, and provoking factors. The aim of the treatment is to maintain the patients free of seizures and to reintegrate them to their usual activities in the society (familiar, scholar, labor, etc.). For the current management of epilepsy we have several pharmacological possibilities that modify favorably the natural history of this disease. In ideal conditions, monotherapy with the most proper drug, in the minimal doses for a complete control of epilepsy should be prescribed. However, one third of patients does not respond adequately and required the addition of other(s) antiepileptic drugs giving rise to politherapy that increase the toxicity and adverse effects. In addition, when pharmacological therapy is insufficient some patients will require surgery (lobectomy, callosotomy, lesionectomy, etc.) or stimulation of central (deep stimulation) or peripheral nervous system (vagal nerve) or cetogenic diet. Therefore, refractory epilepsy to pharmacological management continue to be a true challenge and the rational use of epileptic drugs being the key for recovering the quality of life of the patient that has this unfortunate but fascinating disorder. The present review describes in detail the main guidelines in order to have a rational pharmacological antiepileptic therapy in the patient with epilepsy.


REFERENCES

  1. Hauser WA, Rich SS, Lee JR, Annegers JF, Anderson VE. Risk of recurrent seizures after two unprovoked seizures. N Engl J Med 1998; 338(7): 429-34.

  2. Menon B, Shorwon SD, Ischemic stroke in adults and epilepsy. Epilepsy Res 2009: 87(1): 1-11.

  3. Prasad KN, Prasad A, Verma A, Singh AK. Human cisticercosis and Indian scenario: a review. J Biosci 2008: 33(4): 571-82.

  4. Carpio A, Escobar A, Hauser WA. Cisticercosis and epilepsy: a critical review. Epilepsia 1998; 39(10): 1025-40.

  5. Kuzniecky RI, Knowlton RC. Neuroimaging of epilepsy. Semin Neurol 2002; 3: 279-88.

  6. Herman S. Intractable epilepsy: relapsing, remitting or progressive? Epilepsy Curr 2010; 6: 146-8.

  7. Perucca E. Can drug resistance in epilepsy be minimized? Challenging commonly held beliefs. Epileptic Disord 2005; 7(Suppl. 1): S14-S21.

  8. Beghi E. Treating epilepsy across its different stages. Ther Adv Neurol Disord 2010; 3(2): 85-92.

  9. St Louis EK, Rosenfeld WE, Bramley T Antiepileptic drug monotherapy: the initial approach in epilepsy management. Curr Neuropharmacol 2009; 7(2): 77-82.

  10. Roks G, Deckers CL, Meinardi H, Dirksen R, van Egmond J, van Rijn CM. Effects of polytherapy compared with monotherapy in antiepileptic drugs: an animal study. J Pharmacol Exp Ther 1999; 288(2): 472-7.

  11. Treiman DM. Management of refractory complex partial seizures: current state of the art. Neuropsychiatr Dis Treat 2010; 6: 297-308.

  12. Wendling F, Chauvel P, Biraben A, Bartolomei F. From intracerebral EEG signals to brain connectivity: identification of epileptogenic networks in partial epilepsy. Front Syst Neurosci 2010; 4: 154.

  13. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49(7): 1239-76.

  14. Ben-Menachem E, AAN/AES guidelines on use of new AEDS. Epilepsy Curr 2005; 5(1): 30-2.

  15. Trevisol-Bittencourt PC, da Silva VR, Molinari MA, Troiano AR. Phenytoin as the first option in female epileptic patients? Arq Neuropsiquiatr 1999; 57(3B): 784-6.

  16. French J. The long-term therapeutic management of epilepsy. Ann Intern Med 1994; 1; 120(5): 411-22.

  17. Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, et al. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess 2005; 9(15): 1-157, iii-iv.

  18. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, Kalviainen R, Mattson R, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47(7): 1094-120.

  19. Crawford PM. Managing epilepsy in women of childbearing age. Drug Saf 2009; 32(4): 293-307.

  20. Kanner AM. Advances in epilepsy: new perspectives on new-onset epilepsy, comorbidities, and pharmacotherapy. F1000 Med Rep 2010; 2: 51.

  21. Marson AG, Appleton R, Baker GA, Chadwick DW, Doughty J, Eaton B, Gamble C, Jacoby A, Shackley P, Smith DF, Tudur-Smith C, Vanoli A, Williamson PR. A randomised controlled trial examining the longerterm outcomes of standard versus new antiepileptic drugs. The SANAD trial. Health Technol Assess 2007; 11(37): iii-iv, ix-x, 1-134.

  22. St Louis EK. The Art of Managing Conversions between Antiepileptic Drugs: Maximizing Patient Tolerability and Quality of Life. Pharmaceuticals (Basel) 2010; 3(9): 2956-69.

  23. Jetter GM, Cavazos JE. Epilepsy in the elderly. Semin Neurol 2008; 28(3): 336-41. Epub 2008 Jul 24.

  24. Kanner AM. Psychiatric comorbidity in children with epilepsy ... or is it: epilepsy comorbidity in children with psychiatric disorders? Epilepsy Curr 2008; 8(1): 10-2.

  25. Widjaja E, Li B, Schinkel CD, Ritchie LP, Weaver J, Snead OC, Rutka JT, et al. Cost-effectiveness of pediatric epilepsy surgery compared to medical treatment in children with intractable epilepsy. Epilepsy Res 2011.

  26. Marras CE, Rizzi M, Villani F, Messina G, Deleo F, Cordella R, Franzini A. Deep brain stimulation for the treatment of drug-refractory epilepsy in a patient with a hypothalamic hamartoma. Neurosurg Focus 2011; 30(2).

  27. de Kinderen RJ, Lambrechts DA, Postulart D, Kessels AG, Hendriksen JG, Aldenkamp AP, Evers SM, et al. Research into the (Cost) Effectiveness of the Ketogenic Diet among Children and Adolescents with Intractable Epilepsy: Design of a Randomized Controlled Trial. BMC Neurol 2011; 11(1): 10.




2020     |     www.medigraphic.com